Armata PharmaceuticalsARMP
Market Cap: 105M
About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Employees: 75
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
42% more capital invested
Capital invested by funds: $4.17M [Q4 2023] → $5.93M (+$1.76M) [Q1 2024]
0.36% more ownership
Funds ownership: 3.57% [Q4 2023] → 3.93% (+0.36%) [Q1 2024]
4% less funds holding
Funds holding: 25 [Q4 2023] → 24 (-1) [Q1 2024]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Research analyst outlook
3 Wall Street Analysts provided 1 year price forecasts over the past 6 months
3 analyst ratings
HC Wainwright & Co. Joseph Pantginis | 141%upside $7 | Buy Reiterated | 11 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis | 141%upside $7 | Buy Reiterated | 8 May 2024 |
HC Wainwright & Co. Joseph Pantginis | 141%upside $7 | Buy Maintained | 22 Mar 2024 |